专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012106634A1 USE OF AN ANTI-CD200 ANTIBODY FOR PROLONGING THE SURVIVAL OF ALLOGRAFTS 审中-公开
标题翻译：使用抗CD200抗体来促进ALLOGRAFTS生存
公开(公告)号：WO2012106634A1
公开(公告)日：2012-08-09
申请号：PCT/US2012/023831
申请日：2012-02-03
申请人： ALEXION PHARMACEUTICALS, INC. , WANG, Yi , FAAS MCKNIGHT, Susan , YU, Zhao, Xue , WANG, Hao
发明人： WANG, Yi , FAAS MCKNIGHT, Susan , YU, Zhao, Xue , WANG, Hao
IPC分类号： A61P37/06 , A61K39/395
CPC分类号： C07K16/2803 , A61K9/0019 , A61K31/365 , A61K31/436 , A61K31/439 , A61K31/5377 , A61K38/13 , A61K39/39533 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2300/00 , C07K2317/52 , C07K2317/71 , C07K2317/76 , G01N33/6893 , G01N2333/70596 , G01N2800/245 , G01N2800/347 , G01N2800/56
摘要： The present disclosure provides methods useful for prolonging the survival of an allograft organ in a recipient mammal. The methods include administration of an anti-CD200 antibody or a CD200-binding fragment of the antibody. The disclosure also provides biomarkers, a change in one or more of which indicates that an anti- CD200 antibody has produced a desired immunomodulatory effect in a mammal. Also featured are pharmaceutical compositions, kits, and solutions that contain at least one anti-CD200 antibody and are useful in the methods described herein.
摘要翻译：本公开提供了用于延长受体哺乳动物中同种异体移植器官的存活的方法。所述方法包括施用抗CD200抗体或抗体的CD200结合片段。本公开还提供了生物标志物，其中一个或多个的变化表明抗CD200抗体已经在哺乳动物中产生了所需的免疫调节作用。还特征在于含有至少一种抗CD200抗体的药物组合物，试剂盒和溶液，并且可用于本文所述的方法。

2. 发明公开

EP3359566A1 A METHOD FOR TREATING AGE-RELATED MACULAR DEGENERATION IN A PATIENT 审中-公开
公开(公告)号：EP3359566A1
公开(公告)日：2018-08-15
申请号：EP16785620.2
申请日：2016-10-06
申请人： Alexion Pharmaceuticals, Inc. , Wang, Yi , Rohrer, Barbel
发明人： WANG, Yi , ROHRER, Barbel
IPC分类号： C07K16/18 , A61P27/02 , A61K39/395
CPC分类号： C07K16/18 , A61K2039/505 , A61K2039/54 , C07K2317/622
摘要： The present disclosure relates to, inter alia, a method of treating age-related macular degeneration (AMD) in a patient, comprising administering an effective amount of a C5 inhibitor or a C5a inhibitor.

3. 发明公开

EP3368073A1 A METHOD OF INHIBITING EXACERBATIONS OF T CELL-MEDIATED ALLOGRAFT VASCULOPATHY 审中-公开
公开(公告)号：EP3368073A1
公开(公告)日：2018-09-05
申请号：EP16791271.6
申请日：2016-10-28
申请人： Alexion Pharmaceuticals, Inc. , Yale University , Pober, Jordan , Jane-Wit, Daniel , Qin, Lingfeng , Wang, Yi
发明人： POBER, Jordan , JANE-WIT, Daniel , QIN, Lingfeng , WANG, Yi
IPC分类号： A61K39/395 , A61K39/00 , C07K16/18 , C07K16/40
CPC分类号： A61K39/395 , A61K2039/505 , A61K2039/54 , A61K2039/545 , A61P9/00 , A61P37/06 , C07K16/18 , C07K16/2839 , C07K16/40 , C07K2317/76
摘要： The disclosure provides a method of reducing the likelihood of forming a T cell-mediated allograft vasculopathy lesion in a mammalian transplant recipient comprising transplanting an allograft from a donor to a recipient and administering a therapeutically effective amount of an anti-C5 antibody, or antigen-binding fragment thereof, to the recipient, wherein the anti-C5 antibody, or antigen-binding fragment thereof reduces the likelihood of forming an allograft vasculopathy lesion in the allograft, compared to the absence of treatment with an anti-C5 antibody, or antigen-binding fragment thereof.

4. 发明申请

WO2017075325A1 A METHOD OF INHIBITING EXACERBATIONS OF T CELL-MEDIATED ALLOGRAFT VASCULOPATHY 审中-公开
标题翻译：抑制T细胞介导的同种异体移植物血管病变的方法
公开(公告)号：WO2017075325A1
公开(公告)日：2017-05-04
申请号：PCT/US2016/059279
申请日：2016-10-28
申请人： ALEXION PHARMACEUTICALS, INC. , YALE UNIVERSITY , POBER, Jordan , JANE-WIT, Daniel , QIN, Lingfeng , WANG, Yi
发明人： POBER, Jordan , JANE-WIT, Daniel , QIN, Lingfeng , WANG, Yi
IPC分类号： A61K39/395 , A61K39/00 , C07K16/18 , C07K16/40
CPC分类号： C07K16/18 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/76
摘要： The disclosure provides a method of reducing the likelihood of forming a T cell-mediated allograft vasculopathy lesion in a mammalian transplant recipient comprising transplanting an allograft from a donor to a recipient and administering a therapeutically effective amount of an anti-C5 antibody, or antigen-binding fragment thereof, to the recipient, wherein the anti-C5 antibody, or antigen-binding fragment thereof reduces the likelihood of forming an allograft vasculopathy lesion in the allograft, compared to the absence of treatment with an anti-C5 antibody, or antigen-binding fragment thereof.
摘要翻译：本公开内容提供了降低哺乳动物移植接受者中形成T细胞介导的同种异体移植血管病变损伤的可能性的方法，其包括将同种异体移植物从供体移植到受体并施用治疗有效量的抗-C5抗体或其抗原结合片段与受体接触，其中抗-C5抗体或其抗原结合片段降低了在同种异体移植物中形成同种异体移植血管病损伤的可能性，与不存在抗C5抗体或其抗原结合片段。

5. 发明申请

WO2017062649A1 A METHOD FOR TREATING AGE-RELATED MACULAR DEGENERATION IN A PATIENT 审中-公开
标题翻译：一种治疗患者年龄相关性变性的方法
公开(公告)号：WO2017062649A1
公开(公告)日：2017-04-13
申请号：PCT/US2016/055794
申请日：2016-10-06
申请人： ALEXION PHARMACEUTICALS, INC. , WANG, Yi , ROHRER, Barbel
发明人： WANG, Yi , ROHRER, Barbel
IPC分类号： C07K16/18 , A61P27/02 , A61K39/395
CPC分类号： C07K16/18 , A61K2039/505 , A61K2039/54 , C07K2317/622
摘要： The present disclosure relates to, inter alia, a method of treating age-related macular degeneration (AMD) in a patient, comprising administering an effective amount of a C5 inhibitor or a C5a inhibitor.
摘要翻译：本公开尤其涉及一种治疗患者年龄相关性黄斑变性（AMD）的方法，包括施用有效量的C5抑制剂或C5a抑制剂。

6. 发明申请

WO2006122257A3 NEBULIZATION OF MONOCLONAL ANTIBODIES FOR TREATING PULMONARY DISEASES 审中-公开
公开(公告)号：WO2006122257A3
公开(公告)日：2006-11-16
申请号：PCT/US2006/018269
申请日：2006-05-10
申请人： ALEXION PHARMACEUTICALS, INC. , WANG, Yi
发明人： WANG, Yi
IPC分类号： C07K16/18 , A61K39/395
摘要： The present application relates to methods and compositions employing an antibody that inhibits activation of the complement system and can be used to prevent or treat a pulmonary disease or condition.

7. 发明申请

WO2018071624A1 EFFICACY OF AN ANTI-C5 ANTIBODY IN THE PREVENTION OF ANTIBODY MEDIATED REJECTION IN SENSITIZED RECIPIENTS OF A KIDNEY TRANSPLANT 审中-公开
标题翻译：抗C5抗体在预防肾移植敏化受者抗体介导的排斥反应中的功效
公开(公告)号：WO2018071624A1
公开(公告)日：2018-04-19
申请号：PCT/US2017/056268
申请日：2017-10-12
申请人： ALEXION PHARMACEUTICALS, INC. , GRIFFIN, Herman , WANG, Yi , FREY, Rebecca
发明人： GRIFFIN, Herman , WANG, Yi , FREY, Rebecca
IPC分类号： C07K16/18 , A61K39/395 , A61P37/06
摘要： This disclosure provides methods for reducing antibody mediated rejection (AMR) in a human kidney transplant recipient, comprising administering a therapeutically effective amount of an anti-C5 antibody, or antigen-binding fragment thereof, to the recipient in a phased dosing schedule following reperfusion of a kidney allograft, wherein the recipient is sensitized to a human living donor and wherein the recipient receives about two or more weeks of desensitization therapy prior to transplantation.
摘要翻译：本公开内容提供了用于减少人肾移植接受者中的抗体介导的排斥（AMR）的方法，其包括向接受者施用治疗有效量的抗C5抗体或其抗原结合片段在再灌注肾同种异体移植物之后的分阶段给药方案中，其中所述接受者对人活体供体敏感，并且其中所述接受者在移植前接受约两周或更多周的脱敏治疗。

8. 发明申请

WO2004022096A1 METHOD OF TREATMENT OF ASTHMA USING ANTIBODIES TO COMPLEMENT COMPONENT C5 审中-公开
标题翻译：使用抗体来补充组分C5治疗哮喘的方法
公开(公告)号：WO2004022096A1
公开(公告)日：2004-03-18
申请号：PCT/US2003/027808
申请日：2003-09-05
申请人： ALEXION PHARMACEUTICALS, INC. , WANG, Yi
发明人： WANG, Yi
IPC分类号： A61K39/395
CPC分类号： C07K16/18 , A61K2039/505 , A61K2039/54 , A61K2039/544
摘要： A method of treatment of asthma with a compound which binds to or otherwise blocks the generation and/or activity of one or more complement components such as, for example, a complement-inhibiting antibody. The compound can be administered prophylactically to prevent asthma attacks in known asthmatic individuals or as a therapeutic regimen during asthma attacks.
摘要翻译：用结合或以其它方式阻断一种或多种补体成分（例如补体抑制性抗体）的产生和/或活性的化合物治疗哮喘的方法。该化合物可以预防性施用以预防已知哮喘个体中的哮喘发作或作为哮喘发作期间的治疗方案。

9. 发明申请

WO1997009061A1 TREATMENT OF DIABETES VIA ADMINISTRATION OF HORMONALLY INEFFECTIVE INSULIN 审中-公开
标题翻译：通过管理不正常的胰岛素治疗糖尿病
公开(公告)号：WO1997009061A1
公开(公告)日：1997-03-13
申请号：PCT/US1996014348
申请日：1996-09-05
申请人： ALEXION PHARMACEUTICALS, INC.
发明人： ALEXION PHARMACEUTICALS, INC. , WANG, Yi
IPC分类号： A61K38/28
CPC分类号： A61K38/28
摘要： Novel immunomodulatory methods for both the prevention and treatment of type I diabetes mellitus are provided. These methods comprise the administration of doses containing measured amounts (preferably superphysiologic amounts) of an adjuvant free hormonally ineffective insulin related polypeptide to the patient. Preferably this administration is carried out on a schedule designed to induce apoptosis, anergy, or other modulation of the autoimmune activity of T cells reactive with at least one epitope of the hormonally ineffective insulin related polypeptide. The hormonally ineffective insulin related polypeptide is preferably selected from the group consisting of pre-pro insulin, proinsulin, denatured insulin, insulin chain B, insulin chain A, and insulin chain C, either as whole polypeptides or fragments of these polypeptides. Combinations of these polypeptides may also be administered as long as their combination does not generate a hormonally effective insulin polypeptide. The administration of hormonally ineffective insulin related polypeptides in accordance with the invention results in beneficial effects on the development and severity of type I diabetes.
摘要翻译：提供了用于预防和治疗I型糖尿病的新型免疫调节方法。这些方法包括向患者施用含有测量量（优选超生理学量）的佐剂游离激素无效胰岛素相关多肽的剂量。优选地，该给药按照旨在诱导与激素无效的胰岛素相关多肽的至少一个表位反应的T细胞的自身免疫活性的凋亡，无反应或其他调节的调度进行。激素无效的胰岛素相关多肽优选选自前胰岛素，胰岛素原，变性胰岛素，胰岛素链B，胰岛素链A和胰岛素链C，作为完整多肽或这些多肽的片段。只要它们的组合不产生激素有效的胰岛素多肽，也可以施用这些多肽的组合。根据本发明的激素无效胰岛素相关多肽的施用对I型糖尿病的发展和严重程度产生有益的影响。

10. 发明申请

WO2021067526A1 COMPLEMENT INHIBITORS FOR TREATING DRUG-INDUCED COMPLEMENT-MEDIATED RESPONSE 审中-公开
公开(公告)号：WO2021067526A1
公开(公告)日：2021-04-08
申请号：PCT/US2020/053673
申请日：2020-10-01
申请人： ALEXION PHARMACEUTICALS, INC.
发明人： WANG, Yi , LIU-CHEN, Susan
IPC分类号： A61K39/00 , A61P37/06
摘要： Disclosed herein are methods and compositions for reducing or eliminating a complement-mediated response in a patient receiving treatment for a disease or disorder wherein one or more therapeutic agents is administered to the patient along with one or more complement inhibitors. Administration of the complement inhibitor along with the therapeutic agent results in a reduced or eliminated complement-mediated response, such as a reduction or elimination of symptoms associated with Complement Activation-Related Pseudoallergy (CARPA) or Cytokine Release Syndrome (CRS).

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式